News

Sprout will resubmit the New Drug Application (NDA) for flibanserin, a once-daily treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, by the third quarter. The FDA

In connection with the filing, Arena will receive a milestone payment of $500,000 from Eisai. Arena Pharmaceuticals president and CEO Jack Lief noted with over half of adults

The drug is approved for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed and who have received at least two prior treatment regimens and

The trial of IMAB027, which is a first-in-class monoclonal antibody targeting the tight junction protein Claudin-6 (CLDN6), is being carried out in Germany, Belgium, Russia and Ukraine. Ganymed

The clinical assets include AFN-1252, a FabI inhibitor designated by the FDA as a Qualified Infectious Disease Product (QIDP) which has successfully completed a Phase 2a study for

"We are pleased to offer patients with treatment-resistant schizophrenia a new liquid formulation of clozapine that is FDA approved to treat this difficult condition," said Bruce C. Cozadd,

The company said that Phase III clinical trials in type 1 and type 2 diabetes will commence soon. Merck senior vice president of Diabetes, Global Human Health Matt

The company already has exclusive rights of Cynviloq from Samyang in the US and the 27 countries of the European Union (EU). Sorrento president and chief executive officer

Under the deal, SynCo will manufacture Advaxis’ novel drug candidate, ADXS-HPV as well as assist them in developing scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance